Akebia Therapeutics Inc is a biopharmaceutical company dedicated to developing treatments for kidney diseases. Its main project, Vafseo (vadadustat), targets anemia in chronic kidney disease (CKD) patients, both those undergoing dialysis and those who are not. Additionally, Akebia offers Auryxia, a medication for managing serum phosphorus in dialysis-dependent CKD patients and treating iron deficiency anemia in non-dialysis CKD patients. The company collaborates globally, including with Mitsubishi Tanabe Pharma for vadadustat in Asia. Founded in 2007, Akebia is based in Cambridge, Massachusetts.
Thursday’s additional top analyst upgrades and downgrades included Advanced Micro Devices, Akebia Therapeutics, Dell Technologies, HP, Starwood Property Trust and State Street.
The Friday afternoon analyst calls were focused on Biogen, 3D Systems, Duke Energy, Ford, and more.
Friday's top analyst calls included Akebia Therapeutics, Broadcom, DocuSign, Lululemon Athletica, NextEra Energy, Overstock.com, Shopify and Wayfair.
